Navigation Links
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
Date:11/18/2010

r s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='108929039';s.prop16='CrowdFactory_Share';s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_Share'); }); cf_jq(".cf_dialog_footer button").live("mouseup", function (){ var socialText = this.innerHTML.replace("Post to ", ""); /*s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.prop16='CrowdFactory_'+socialText; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='108929039';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

MISSISSAUGA, ON, Nov. 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.

YM also announced that the trial protocol has been extended to allow patients who have derived a clinical benefit to continue to receive treatment beyond the nine cycles of the core protocol. Subjects enrolled in the extension protocol will be evaluated every three months for up to 24 cycles of CYT387 treatment.

"The initiation of this trial at additional sites reflects the growing investigator interest for CYT387 and will help ensure the timely achievement of our enrolment targets. Receiving clearance to extend the protocol and allow patients to remain on CYT387 therapy further d
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
3. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
4. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
5. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
8. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
10. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
11. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... 2014 Local veterinary surgeon, Dr. Tim ... study of donor stem cells for dogs with osteoarthritis. ... and has performed clinical stem cell therapy for 7 ... determine if a single injection of donor stem cells ... reduce pain and inflammation in the treated joints. ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Bulletin Board: IAGX), announced today that William Spencer, President and ... the 2nd annual LD MICRO Conference on Thursday, December 3rd, ... Angeles. , About LD MICRO , LD MICRO is a ... in the micro-cap space. Since 2002, the firm has published ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical ... results for the third quarter ended September 30, 2009. ... of this year, the FDA,s Arthritis Advisory Committee unanimously ... XIAFLEX(TM) for the treatment of Dupuytren,s disease, and we ...
... Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading ... that Christopher Sears, Ph.D. has joined the company,s ... focused on designing and commercializing novel molecular diagnostics ... the development of computational biology systems for several ...
Cached Biology Technology:Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4
(Date:10/16/2014)... of Marine Science have received a 3-year, $392,773 ... the streams and wetlands most vulnerable to sea-level ... governments and citizens conserve these important ecosystems. , ... tidal-marsh observations first gathered by VIMS scientists in ... today,s researchers accurately map the slow but inexorable ...
(Date:10/16/2014)... women experienced improvements in vaginal atrophy, with no ... after 12 weeks of daily 10 milligram (mg) ... supplement previously shown to help relieve certain menopause ... reported in a poster at the North American ... "These data documented improved vaginal epithelium, without significant ...
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... broad review of current research on nuclear power economics has ... Energy . The report concludes that nuclear power will continue ... fuel cycle is not sustainable. Due to uncertainty about waste ... basic assumptions that are not grounded in real data. ...
... DURHAM, N.C. As the U.S. Environmental Protection Agency ... a Duke University study identifies new monitoring protocols and ... predict the ecological impacts of coal ash contaminants. ... and where we look for coal ash contaminants," says ...
... , Ananth Annapragada, Ph.D., Robert H. Graham Professor in ... of Texas Health Science Center at Houston (UTHealth), has ... American Institute for Medical and Biological Engineering. Annapragada, ... of Biomedical Informatics, will be inducted during the AIMBE,s ...
Cached Biology News:Duke scientists look deeper for coal ash hazards 2UTHealth School of Biomedical Informatics professor to be inducted to AIMBE College of Fellows 2